Rita S. Guenther – författare

The National Research Council hosted an interacademy workshop in Yekaterinburg, Russia together with the Russian Academy of Sciences in October 2004 as a means of exploring various aspects of industrial innovation in the Urals region of Russia. Workshop presenters focused on the establishment of cooperative business partnerships between Russian industrial companies and Russian research organizations, particularly those in the closed nuclear cities of Russia. The concept of "market pull" was therefore an important aspect of the workshop, including partnerships between Russian researchers and international companies, as well as those with international research centers. However, given the complex economic and research climates in Russia, which are intensified in the nuclear cities, cooperation between Russian industry and Russian researchers were of primary during the workshop presentations and subsequent discussions as captured in this workshop summary.

Scientists, engineers, and medical professionals play a vital role in building the 21st- century science and technology enterprises that will create solutions and jobs critical to solving the large, complex, and interdisciplinary problems faced by society: problems in energy, sustainability, the environment, water, food, disease, and healthcare. As a growing percentage of the scientific and technological workforce, women need to participate fully not just in finding solutions to technical problems, but also in building the organizations responsible for the job creation that will bring these solutions to market and to bear on pressing issues. To accomplish this, it is important that more women in science and engineering become entrepreneurs in order to start new companies; create business units inside established organizations, mature companies, and the government; and/or function as social entrepreneurs focused on societal issues. Entrepreneurship represents a vital source of change in all facets of society, empowering individuals to seek opportunity where others see insurmountable problems.From Science to Business: Preparing Female Scientists and Engineers for Successful Transitions into Entrepreneurship is the summary of an August 2009 workshop that assesses the current status of women undertaking entrepreneurial activity in technical fields, to better understand the nature of the barriers they encounter, and to identify what it takes for women scientists and engineers to succeed as entrepreneurs. This report focuses on women's career transitions from academic science and engineering to entrepreneurship, with a goal of identifying knowledge gaps in women's skills as well as experiences crucial to future success in business and critical for achieving leadership positions in entrepreneurial organizations. From Science to Business makes the case that in addition to educating women scientists and engineers in rigorous problem solving, it is equally important to provide exposure and training to impart the skills that will enable more women to move from the role of expert to that of leader in dynamic new business enterprises.This book will be of interest to professionals in both academia and industry, graduate and post-graduate students, and organizations that advocate for a stronger economy.

Thousands of gifted individuals, including women and underrepresented minorities, remain a disproportionally small fraction of those in science, technology, engineering, and math (STEM) careers. Industry, as the largest employer category of those with STEM backgrounds, stands to benefit considerably from greater inclusion of women and underrepresented minorities in the workforce. However, nothing short of a game-changing environment must be created to harness the talent of those not fully represented in the STEM workforce. Advancing Diversity in the US Industrial Science and Engineering Workforce is the summary of a workshop held in May, 2012 by the National Academy of Engineering, focusing on the needs and challenges facing industry in particular, and it is intended to facilitate further discussion and actions to address these complex issues. The workshop provided a forum for leaders from industry, academia, and professional associations to share best practices and innovative approaches to recruiting, retaining, and advancing women and underrepresented minorities in the scientific and engineering workforce throughout the nation's industries.

To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resistant tuberculosis (MDR TB)-a disease caused by strains of Mycobacterium tuberculosis (M.tb.) resistant to two primary TB drugs (isoniazid and rifampicin)-face lengthy treatment regimens of 2 years or more with daily, directly observed treatment (DOT) with SLDs that are less potent, more toxic, and more expensive than those used to treat drug-susceptible TB. From 2000 to 2009, only 0.2-0.5 percent of the estimated 5 million MDR TB cases globally were treated with drugs of known quality and in programs capable of delivering appropriate care (Keshavjee, 2012). The vast majority of MDR TB patients either died from lack of treatment or contributed to the spread of MDR TB in their communities. A strengthened global supply chain for SLDs could save lives by consistently delivering high quality medicines to more of the people who need them.This public workshop explored innovative solutions to the problem of how to get the right SLDs for MDR TB to people who critically need them. More specifically, the workshop examined current problems and potential opportunities for coordinated international efforts to ensure that a reliable and affordable supply of high-quality SLDs is available. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary covers the objectives of the workshop, which were to review: -To what extent and in what ways current mechanisms are or are not effectively accomplishing what is needed, including consideration of bottlenecks. -The advantages and disadvantages of centralization in the management of the global drug supply chain, and potential decentralized approaches to improve operations of the supply chain. -What can be learned from case studies and examples from other diseases (e.g., the Affordable Medicines Facility-malaria (AMFm) and the U.S.President's Emergency Plan for AIDS Relief [PEPFAR]) - The current allocation of responsibilities and roles of the private (including industry and nonprofit public health organizations) and public sectors, and examination of opportunities for enhancing and optimizing collaboration -Identification of potential innovative solutions to the problem